OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Westin on Early Findings With Azenosertib in High-Grade Serous Ovarian Cancer

April 11th 2024

Shannon N. Westin, MD, MPH, FACOG, discusses the DENALI trial of azenosertib in patients with high-grade serous ovarian cancer.

Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple Myeloma

April 11th 2024

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Overman on Future Research Directions in GI Cancer

April 11th 2024

Michael J. Overman, MD, discusses future research directions in gastrointestinal cancers.

Dr Efstathiou on the Evolution of Trimodal Therapy in MIBC

April 11th 2024

Jason Efstathiou, MD, DPhil, discusses the utility of trimodal therapy in patients with muscle-invasive bladder cancer.

Dr Nassar on MMR Determination by IHC and NGS in CRC and Endometrial Cancer

April 11th 2024

Amin Nassar, MD, discusses the investigation of NGS plus standard IHC to detect dMMR status in patients with colorectal cancer or endometrial cancer.

Dr Park on the Initial Efficacy of Epacadostat Plus Preoperative Chemoradiation in Rectal Cancer

April 11th 2024

Haeseong Park, MD, MPH, discusses phase 1 results of epacadostat plus preoperative chemoradiation in locally advanced rectal cancer.

Dr Goetz on the Early Pharmacokinetic Data With Neoadjuvant (Z)-endoxifen in ER+/HER2– Breast Cancer

April 11th 2024

Matthew P. Goetz, MD, discusses pharmacokinetic data for neoadjuvant (Z)-endoxifen in estrogen receptor–positive, HER2-negative breast cancer.

Dr Koo on the Clinical Utility of PSMA PET in Prostate Cancer

April 11th 2024

Phillip J. Koo, MD, discusses the clinical use of PSMA PET imaging in patients with prostate cancer.

Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial Cancer

April 10th 2024

Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.

Dr Usmani on the Optimal Role for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 10th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the optimal role for ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Sahin on the Design of the Northstar Response Assay in Advanced GI Cancer

April 10th 2024

Ilyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.

Dr Dholaria on the Use of Liso-Cel in Relapsed/Refractory CLL

April 10th 2024

Bhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC

April 10th 2024

Dr Christenson on Copanlisib Plus Nivolumab in Pretreated PIK3Ca+ MSS mCRC

April 9th 2024

Eric S. Christenson, MD, discusses efficacy data for copanlisib plus nivolumab in patients with pretreated, MSS metastatic colorectal cancer.

Dr Richardson on the Safety of Upifitamab Rilsodotin in Platinum-Resistant Ovarian Cancer

April 9th 2024

Debra L. Richardson, MD, FACS, FACOG, discusses the safety profile of upifitamab rilsodotin in the phase 1/2 UPLIFT trial of patients with ovarian cancer.

Dr Overman on Nonoperative Cancer Management in GI Malignancies

April 9th 2024

Michael J. Overman, MD, discusses the rationale for utilizing a nonoperative management approach over traditional surgery in gastrointestinal cancers.

Dr Bochner on Bladder-Sparing Regimens in MIBC

April 9th 2024

Bernard H. Bochner, MD, FACS, discusses ongoing studies evaluating the potential bladder-sparing options for patients with muscle-invasive bladder cancer.

Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL

April 9th 2024

Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.

Dr Garmezy on Factors Influencing Treatment Selection in Variant RCC

April 9th 2024

Benjamin Garmezy, MD, discusses key factors influencing treatment selection for patients with variant renal cell carcinoma.

Dr Srour on the Safety and Efficacy of the Allogeneic CAR T-Cell Therapy CTX130 in Advanced ccRCC

April 9th 2024

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.